At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 3, 2026 at 08:05 ET
Harmony Biosciences filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, where shareholders will vote on the election of four Class III directors, ratification of Deloitte as auditors, and an advisory vote on executive compensation. This filing follows a recent 8-K report disclosing executive changes, including the appointment of Peter Anastasiou as COO and board member Troy Ignelzi, while two other directors stepped down. The cross-filing context suggests these board appointments are materializing as part of the proxy fight materials.
- Filed a definitive proxy statement (DEFA14A) for the 2026 annual meeting.
- Shareholders will vote on the election of four Class III directors: Geno J. Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki, Ph.D.
- Shareholders will vote on ratifying Deloitte & Touche LLP as the independent registered public accounting firm.
- Shareholders will vote on a non-binding, advisory vote on the compensation of named executive officers.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access